Microsoft Word - S_2019_GRC-02_025_S43 Share Acquisition_EN Page 1 – Translation – GRC-02/2019/025 11 December 2019 Subject: Report of the Asset Acquisition To: President The Stock Exchange of

company will sign the share purchase agreement after receiving approval from the Extraordinary General Meeting of Shareholders by 15th August 2020 and is expected to be able to pay and transfer the shares

Ref. WINNER 0009/20108 Page 1 of 10 Disclosures on the asset acquisition of Winner Group Enterprise Public Company Limited on share purchase of Aesthetic Zecret (At-Ze) Company Limited (Schedule 1

transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging

into the sign of Share Sale and Purchase Agreement, including transfer of related brand names from the selling shareholder(s). According to the Notification of the Capital Market Supervisory Board No

system of new medicines according to the additional standards SET forth by the Food and Drug administration. Therefore, it is necessary to use the capital to proceed the project amount 32,000,000 baht

recognition Drug license Manufacturing service (OEM) Contracts with a customer ▪ บรษัิทยาท าสญัญาขายทะเบยีนต ารับยาทีไ่ดข้ ึน้ ทะเบยีนยากบั อย. แลว้ ใหล้กูคา้ ▪ ลกูคา้ยังไมไ่ดรั้บโอน ทะเบยีนต ารับยาตาม กฎหมาย

2.04 -13.23% 2.15 2.27 -4.99% Finance costs (32.49) (34.40) -5.55% (62.48) (66.64) -6.24% Share of profit of investment in associate 0.61 0.81 -23.85% 1.50 1.47 1.63% Tax expense (75.16) (64.61) 16.34

and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31

warning on issues. BP saw such an earthquake in its share price after the Gulf oil spill disaster prompted engaged investors to use their voting rights to call for the removal of the chair of the board’s